Ritlecitinib
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: litfulo, PF-06651600, ritlecitinib tosylate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ritlecitinib is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2023. DrugCentral lists 9 molecular targets, including ITK, JAK3 and TXK. Recorded indications include Alopecia areata.
- Approval status: onp (first approved 2023 by the FDA).
- Molecular targets: ITK, JAK3, TXK and BMX (9 listed in DrugCentral).
- Indications: Alopecia areata.
- ATC code: L04AF08 (Janus-associated kinase (JAK) inhibitors).
- Molecular formula: C15H19N5O; molecular weight 285.35 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Alopecia areata
Mechanism & targets
Molecular targets (9)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Tyrosine-protein kinase ITK/TSK | ITK | unknown | Ki 7.57 |
| Tyrosine-protein kinase JAK3 | JAK3 | inhibitor | IC50 7.48 |
| Tyrosine-protein kinase TXK | TXK | unknown | Ki 6.88 |
| Cytoplasmic tyrosine-protein kinase BMX | BMX | unknown | Ki 6.26 |
| Tyrosine-protein kinase Tec | TEC | unknown | IC50 6.23 |
| Tyrosine-protein kinase BTK | BTK | unknown | IC50 6.22 |
| Tyrosine-protein kinase JAK1 | JAK1 | inhibitor | IC50 5.79 |
| Tyrosine-protein kinase Blk | BLK | unknown | IC50 4.72 |
| Receptor tyrosine-protein kinase erbB-4 | ERBB4 | unknown | IC50 4.60 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-09-15 | EMA | — | PFIZER EUROPE MA EEIG | |
| 2023-06-26 | PMDA | — | Pfizer Japan Inc. | |
| 2023-06-23 | FDA | — | PFIZER INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AF08 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Janus-associated kinase (JAK) inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Drug ineffective | 324.5 |
| Therapeutic product effect incomplete | 298.6 |
| Condition aggravated | 128.1 |
| Acne | 81.7 |
| Blood creatine phosphokinase increased | 75.8 |
| Product dose omission issue | 56.7 |
| Off label use | 51.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ritlecitinib is on its molecule page.
| Molecular formula | C15H19N5O |
|---|---|
| Molecular weight | 285.35 g/mol |
| CAS number | 1792180-81-4 |
| InChIKey | CBRJPFGIXUFMTM-WDEREUQCSA-N |
| PubChem CID | 118115473 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ritlecitinib used for?
DrugCentral lists the following indications for Ritlecitinib: Alopecia areata.
How does Ritlecitinib work?
Its molecular targets in DrugCentral include ITK, JAK3 (inhibitor), TXK and BMX.
When was Ritlecitinib first approved?
Ritlecitinib was first approved by the FDA in 2023.
What is the chemical formula of Ritlecitinib?
Ritlecitinib has the molecular formula C15H19N5O and a molecular weight of 285.35 g/mol.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5728 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4085457 — compound record and bioactivity
- PubChem CID 118115473 — chemical identifiers
- DrugBank DB14924 — drug record
- FDA UNII 2OYE00PC25 — substance identity
- DailyMed: FDA labels for Ritlecitinib — current prescribing information (label search)
- UniProt Q08881 (ITK) — target protein
- UniProt P52333 (JAK3) — target protein
- UniProt P42681 (TXK) — target protein
- UniProt P51813 (BMX) — target protein
- UniProt P42680 (TEC) — target protein
- UniProt Q06187 (BTK) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.